Lucy N John1,2,3,4, Camila Gonzalez-Beiras3, Marti Vall-Mayans3, Reman Kolmau5, Wendy Houinei1, James Wangi6, Michael Marks7,8,9, Oriol Mitja3,4,5. 1. National Department of Health - Aopi Centre, Port Moresby, Papua New Guinea. 2. Barcelona Institute for Global Health - Faculty of Medicine, University of Barcelona, Barcelona, Spain. 3. Fight AIDS and Infectious Diseases Foundation, Hospital Germans Trias Pujol, Badalona, Catalonia (Spain). 4. School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea. 5. Lihir Medical Centre, International SOS, Lihir Island, Papua New Guinea. 6. WHO PNG Office - Aopi Centre, Port Moresby, Papua New Guinea. 7. London School of Hygiene and Tropical Medicine, London, United Kingdom. 8. Hospital for Tropical Diseases, London, United Kingdom. 9. Division of Infection and Immunity, University College London, London, United Kingdom.
Abstract
INTRODUCTION: Neglected tropical diseases control programmes run separately. For settings with more than one endemic disease, combined mass drug administration (MDA) has potential practical advantages compared with separate programmes but needs confirmation of safety. We assessed the safety of combined MDA for multiple neglected tropical diseases using ivermectin, diethylcarbamazine, albendazole (IDA) and azithromycin (AZI). METHODS: We conducted an open-label, cluster-randomized trial involving individuals living in 34 wards (smaller administrative division) in two study sites, Namatanai District and Lihir Island, Papua New Guinea. We randomly assigned wards to the combined treatment arm (which received a single dose of the triple combination IDA and a single dose of AZI at the same visit) or the control arm (which received IDA separately followed by AZI separately one week after). All participants underwent safety assessments one day after drug administration. Methodology for collecting the adverse events (AEs) was a general question (in Namatanai) and individual questions about specific AEs (in Lihir). The primary endpoint was the prevalence of AEs. Safety of combined treatment was taken to be non-inferior to that of IDA if the upper limit of the two-sided CI for the difference in rates was equal or lower than 5%. FINDINGS: The study enrolled 15,656 participants. Of those enrolled, 7,281 (46.3%) received the combined regimen and 8,375 (53.3%) received standard treatment with IDA for lymphatic filariasis between Nov 1, 2018, and Apr 15, 2019. Of the individuals in the control group, 4,228 (50.5%) attended a second visit one week apart to receive AZI for yaws. In Namatanai, the proportion of AEs was similar in the combined group (0.8%) compared to the IDA group (1.3%, difference 0.5% [95CI -2.5% to 1.4%]) or the AZI group (3.6%, d -2.8% [95CI -8.6% to 2.8%]). In Lihir, the proportion of AEs was higher in the combined group (23.0%) compared to the IDA group (12.2%, d 10.8% [95% CI 1.5% to 20.2%]) or the AZI group (11.1%, d 11.9% [95% CI 2.7% to 21.1%]).We observed 21 (0.3%) grade-2 AEs in the combined treatment group, 33 (0.4%) in the IDA separately group, and 18 (0.2%) in the AZI separately group. No participants required treatment for any AE. We observed no deaths, serious AEs, or AEs of special interest. INTERPRETATION: In the largest trial so far involving coadministration of regimens based on IDA and AZI, the combination was safe and feasible in a population of more than 15,000 people. Combined MDA based on these two regimens opens up new potential for the control of neglected tropical diseases in the Western Pacific region.
INTRODUCTION: Neglected tropical diseases control programmes run separately. For settings with more than one endemic disease, combined mass drug administration (MDA) has potential practical advantages compared with separate programmes but needs confirmation of safety. We assessed the safety of combined MDA for multiple neglected tropical diseases using ivermectin, diethylcarbamazine, albendazole (IDA) and azithromycin (AZI). METHODS: We conducted an open-label, cluster-randomized trial involving individuals living in 34 wards (smaller administrative division) in two study sites, Namatanai District and Lihir Island, Papua New Guinea. We randomly assigned wards to the combined treatment arm (which received a single dose of the triple combination IDA and a single dose of AZI at the same visit) or the control arm (which received IDA separately followed by AZI separately one week after). All participants underwent safety assessments one day after drug administration. Methodology for collecting the adverse events (AEs) was a general question (in Namatanai) and individual questions about specific AEs (in Lihir). The primary endpoint was the prevalence of AEs. Safety of combined treatment was taken to be non-inferior to that of IDA if the upper limit of the two-sided CI for the difference in rates was equal or lower than 5%. FINDINGS: The study enrolled 15,656 participants. Of those enrolled, 7,281 (46.3%) received the combined regimen and 8,375 (53.3%) received standard treatment with IDA for lymphatic filariasis between Nov 1, 2018, and Apr 15, 2019. Of the individuals in the control group, 4,228 (50.5%) attended a second visit one week apart to receive AZI for yaws. In Namatanai, the proportion of AEs was similar in the combined group (0.8%) compared to the IDA group (1.3%, difference 0.5% [95CI -2.5% to 1.4%]) or the AZI group (3.6%, d -2.8% [95CI -8.6% to 2.8%]). In Lihir, the proportion of AEs was higher in the combined group (23.0%) compared to the IDA group (12.2%, d 10.8% [95% CI 1.5% to 20.2%]) or the AZI group (11.1%, d 11.9% [95% CI 2.7% to 21.1%]).We observed 21 (0.3%) grade-2 AEs in the combined treatment group, 33 (0.4%) in the IDA separately group, and 18 (0.2%) in the AZI separately group. No participants required treatment for any AE. We observed no deaths, serious AEs, or AEs of special interest. INTERPRETATION: In the largest trial so far involving coadministration of regimens based on IDA and AZI, the combination was safe and feasible in a population of more than 15,000 people. Combined MDA based on these two regimens opens up new potential for the control of neglected tropical diseases in the Western Pacific region.
Authors: M J Bockarie; J L Hii; N D Alexander; F Bockarie; H Dagoro; J W Kazura; M P Alpers Journal: Med Vet Entomol Date: 1999-05 Impact factor: 2.739
Authors: Oriol Mitjà; Wendy Houinei; Penias Moses; August Kapa; Raymond Paru; Russell Hays; Sheila Lukehart; Charmie Godornes; Sibauk Vivaldo Bieb; Tim Grice; Peter Siba; David Mabey; Sergi Sanz; Pedro L Alonso; Kingsley Asiedu; Quique Bassat Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Paul M Emerson; Matthew Burton; Anthony W Solomon; Robin Bailey; David Mabey Journal: Bull World Health Organ Date: 2006-08 Impact factor: 9.408
Authors: Christopher L King; James Suamani; Nelly Sanuku; Yao-Chieh Cheng; Samson Satofan; Brooke Mancuso; Charles W Goss; Leanne J Robinson; Peter M Siba; Gary J Weil; James W Kazura Journal: N Engl J Med Date: 2018-11-08 Impact factor: 91.245
Authors: Lucia Romani; Michael Marks; Oliver Sokana; Titus Nasi; Bakaai Kamoriki; Handan Wand; Margot J Whitfeld; Daniel Engelman; Anthony W Solomon; Andrew C Steer; John M Kaldor Journal: Lancet Glob Health Date: 2018-10 Impact factor: 38.927
Authors: Allan M Ciciriello; Jessica K Fairley; Emma Cooke; Paul M Emerson; Pamela J Hooper; Birgit Bolton; Genevieve LaCon; David G Addiss Journal: PLoS Negl Trop Dis Date: 2022-09-29